Literature DB >> 17912073

Multicenter study of wound healing in neurofibromatosis and neurofibroma.

Takeshi Miyawaki1, Brian Billings, Yaron Har-Shai, Pius Agbenorku, Elisa Kokuba, Andrea Moreira-Gonzalez, Mari Tsukuno, Kunihiro Kurihara, Ian T Jackson.   

Abstract

Based on clinical experience, the senior author has become convinced that wounds produced to correct the deformities of patients with neurofibromatosis (NF-1) have produced remarkably good scars, the interesting feature being that progression to keloid or hypertrophic scar is rare. The other point noted was that this situation did not change, no matter the patient's race or skin color. There have been few reports describing or discussing this hypothesis. The purpose of this study was to investigate whether wounds produced in the patients with NF-1 produce keloid or hypertrophic scars. The patients with solitary neurofibroma were also included in this study; these were compared with the NF-1 group. This was conducted as a multicenter study. Patients with neurofibromatosis/solitary neurofibroma, who were operated on from 1990 to 2000, were evaluated by reviewing their medical charts and photographs retrospectively. The patients were treated in centers from five different countries. The analysis was undertaken based on the following points: 1) age and sex at surgery; 2) race of the patients; 3) past and family histories of hypertrophic scar and keloid; 4) surgical site(s); 5) diagnosis, NF1 or solitary neurofibroma; 6) surgical complications; 7) number of reoperations to manage the complications; 8) adjuvant therapy for the tumor; 9) depth of the tumors; and 10) incidence of malignant degeneration. A total of 101 cases with neurofibromatosis or solitary neurofibroma was analyzed. The age at surgery ranged from 1 year 6 months to 74 years; sex ratio was 47 males and 54 females. The racial distribution of the patients was 13 white, 13 black, 3 Hispanic, and 58 Asian. There was no past or family history of hypertrophic scar or keloid. The surgical sites were head and neck in 70 cases, trunk in 20 cases, upper extremities in 22 cases, and lower extremities in 20 cases. The clinical diagnosis was NF-1 in 57 cases, solitary neurofibroma in 35 cases, plexiform neurofibroma in four cases, and no distinct clinical diagnosis in five cases. There were no other types of neurofibromatosis. Hematoma and white wide scar were the main postoperative complications found in six cases of NF-1. Infection was also noted in four cases. However, no patient developed hypertrophic scar or keloid in the neurofibromatosis group, whereas two cases showed hypertrophic scar in the solitary neurofibroma group. The outcome showed that the patients with NF-1 and plexiform neurofibroma, no matter the racial group, produce good scars without keloid or hypertrophic changes, whereas solitary neurofibroma has a potential to cause hypertrophic scar.

Entities:  

Mesh:

Year:  2007        PMID: 17912073     DOI: 10.1097/scs.0b013e31811f3587

Source DB:  PubMed          Journal:  J Craniofac Surg        ISSN: 1049-2275            Impact factor:   1.046


  4 in total

1.  Peripheral nerve sheath tumors of the upper extremity and hand in patients with neurofibromatosis type 1: topography of tumors and evaluation of surgical treatment in 62 patients.

Authors:  Reinhard E Friedrich; Caroline Diekmeier
Journal:  GMS Interdiscip Plast Reconstr Surg DGPW       Date:  2017-12-05

2.  Clinical and humanistic burden among pediatric patients with neurofibromatosis type 1 and plexiform neurofibroma in the USA.

Authors:  Xiaoqin Yang; Hyun Kyoo Yoo; Suvina Amin; Wendy Y Cheng; Sanjana Sundaresan; Lujia Zhang; Mei Sheng Duh
Journal:  Childs Nerv Syst       Date:  2022-05-17       Impact factor: 1.532

3.  Ruptured tibial artery in neurofibromatosis type 1: A case report.

Authors:  Sohei Matsuura; Takuya Hashimoto; Masamitsu Suhara; Juno Deguchi
Journal:  Int J Surg Case Rep       Date:  2021-05-26

Review 4.  Mechanobiological dysregulation of the epidermis and dermis in skin disorders and in degeneration.

Authors:  Rei Ogawa; Chao-Kai Hsu
Journal:  J Cell Mol Med       Date:  2013-05-15       Impact factor: 5.310

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.